More Information On Gardasil

Way back in 2007 the Institute For Principled Policy Led the fight to oppose mandatory Gardasil vaccinations for girls as young as 10. Gardasil is a vaccination created to immunize against a limited number of strains of the Human Papilloma Virus (HPV). It was being touted as a cervical cancer prevention method. We cited a complete lack of information on vital statistics regarding length of anti-viral activity, adverse immunological effects, possible adverse reactions (Guillain-Barre Syndrome, etc), actual statistical analysis regarding reduction of cancer, etc. For a complete list of the questions we were asking in the Spring of 2007 you can read our main article HERE.

Now, 3 years later, the bloom is off the “miracle vaccination” rose. It is becoming clear that the objections we raised were more than justified. Merck & Co. the pharmaceutical giant that developed this vaccine and has spent millions trying to guarantee itself indemnity from lawsuit via a little known section of the PATRIOT Act that makes mandatory vaccinations immune from damage lawsuits. That’s what was going on in Ohio in 2007 and we at the Institute For Principled Policy exposed it early, thus killing the bill (HB 81) that would have made the vaccine mandatory.

Since that time there have been nearly 9000 adverse reaction reports, including deaths, paralysis, mysterious pain, immunological impacts, reports of passing out, etc. Now Merck & Co. are trying to get boys in the act, claiming the vaccine will work in them, as well.

Here is a video that gives an interesting overview of the situation including a CBS Evening News report on Gardasil adverse reactions-


There is also a very well done video response to the first video that looks at the problem from a more scientific perspective. It targets both the medical journals and marketing of the vaccine-


As the second video makes clear, there are many questions that MUST be answered about Gardasil primarily but also many other vaccinations. Vaccinations can be wonderful things (polio), but there is an immunological price to pay for their use. The extent of that price is not yet fully known. As consumers we need to be given considerably more information on that price than we now have.